SRC and Miyoshi myopathy: The availability of FDA-approved potent inhibitors of SRC family PTK such as ponatinib, bosutinib, and dasatinib (Table 1) provides an opportunity to evaluate their clinical impact potential for MM patients in proof-of-concept clinical studies.